申请人:Pfizer Inc.
公开号:US20040063688A1
公开(公告)日:2004-04-01
A compound of the formula
1
wherein a, b, c R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, Q, W, Y, and Z are defined as above, useful as potent and selective inhibitors of MIP-1&agr; (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
一种具有下列公式1的化合物,其中a、b、c、R1、R2、R3、R4、R5、R6、Q、W、Y和Z的定义如上所述,用作MIP-1α(CCL3)选择性抑制剂,其结合于其受体CCR1上,该受体存在于炎症和免疫调节细胞上(优选为白细胞和淋巴细胞)。